Table 1 Baseline demographics and clinical characteristics of patients.
Characteristics | N (Proportion, %) |
|---|---|
Total | 32 |
Median Ages (years) | 56 (36–77)a |
Gender | |
Female | 17 (53.1) |
Male | 15 (47.9) |
Smoking status | |
Never smoker | 22 (68.8) |
Current or ex-smoker | 10 (31.2) |
Histologic diagnosis | |
Adenocarcinoma | 26 (81.3) |
Squamous carcinoma | 5 (15.6) |
Others | 1(3.1) |
Stage | |
IIIA (N2) | 21 (65.6) |
IIIB (T4N0 or 1) | 11 (34.4) |
Types of EGFR mutation | |
L858R | 3 (9.4) |
19 deletion | 8 (25.0) |
Wild-type | 15 (46.9) |
Untested | 6 (18.8) |
NACT regimen | |
Paclitaxel-based | 9 (28.1) |
Pemetrexed-based | 15 (46.9) |
TKI-based | 8 (25.0) |
Down-staging | |
Yes | 16 (50.0) |
No | 16 (50.0) |
NACT efficacy | |
Partial response | 18 (56.2) |
Stable or progression | 14 (43.8) |
